- Healthcare AI stock Ventripoint Diagnostics (TSXV:VPT) and ASCEND Cardiovascular are announcing a new integrated product
- The cardiovascular workflow solution promises to rival current market offerings thanks to its end-to-end capabilities and AI-powered infrastructure
- Ventripoint Diagnostics offers products that provide accurate volumetric cardiac measurements equivalent to MRI
- Ventripoint Diagnostics (TSXV:VPT) opened with a gain of 3.57 per cent trading at $0.29 per share
Healthcare AI stock Ventripoint Diagnostics (TSXV:VPT) and ASCEND Cardiovascular are announcing a new integrated product.
ASCEND Cardiovascular develops cardiovascular solutions that deliver seamless workflows across structured reporting, image visualization, collaboration and analytics to improve efficiency, outcomes and ROI. The company’s technology has been installed in more than 1,000 top-ranked healthcare facilities and more than 600 health systems with approximately 50,000 users across the United States.
The companies have combined Ventripoint’s AI-powered 3D Echo software application with ASCEND’s diagnostic viewer, InView, and reporting application, Cardiovascular Structured Reporting, to form a cardiovascular workflow product that “provides an end-to-end solution that rivals other products on the market,” according to a statement released Friday.
The companies believe the product will improve the diagnosis and monitoring of fetal, pediatric and adult congenital heart disease through a “streamlined, smart and effective” approach to cardiology reading and reporting.
“We are excited to embark on this collaborative journey with ASCEND Cardiovascular,” stated Alvira Macanovic, Ventripoint’s president and CEO. “We see this collaboration evolving progressively in its possibilities. We believe that by integrating Ventripoint’s technology in diagnostic medical imaging with ASCEND’s expertise in cardiology IT this will be a successful integrated product. The product will offer a seamless and comprehensive approach to diagnosing and treating cardiovascular conditions.”
“This is an important milestone and validation of ASCEND’s commitment to providers caring for children with heart disease. We are excited to enable the routine, efficient use of Ventripoint’s advanced 3D image analysis in pediatric cardiology,” Jeff Soble, CEO of ASCEND, said in a statement.
Ventripoint and ASCEND will officially debut their integrated product at the 8th World Congress of Pediatric Cardiology and Cardiac Surgery in Washington, D.C., later this month.
Ventripoint Diagnostics specializes in applying AI to echocardiography. Its products provide accurate volumetric cardiac measurements equivalent to MRI.
Ventripoint Diagnostics (TSXV:VPT) opened with a gain of 3.57 per cent trading at $0.29 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Ventripoint Diagnostics Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.